Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Bunkyo, TokyoFounded 19412,979 employeesWebsite
A leading R&D-based pharmaceutical company specializing in neurology and oncology. Known globally for its Alzheimer's treatments and its 'hhc' (human health care) philosophy.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Americas Pharmaceutical Business | 40% | ¥300.4B | ¥174.4B | 58.0% |
| Japan Pharmaceutical Business | 31% | ¥229.2B | ¥73.0B | 31.8% |
| China Pharmaceutical Business | 18% | ¥130.7B | ¥59.3B | 45.4% |
| EMEA Pharmaceutical Business | 11% | ¥81.5B | ¥30.4B | 37.3% |
Close (Oct 30, 2026)
¥5,052+11.5% (1Y)
Eisai +11.5% over 1Y, 1.1pt below the industry average (23 companies, +12.6%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥825.4B | ¥44.1B | ¥38.6B | ¥1.4T | +4.6% |
| 2025FY | ¥789.4B | ¥54.4B | ¥46.4B | ¥1.4T | +6.4% |
| 2024FY | ¥741.8B | ¥53.4B | ¥42.4B | ¥1.4T | -0.4% |
| 2023FY | ¥744.4B | ¥40.0B | ¥55.4B | ¥1.3T | -1.6% |
| 2022FY | ¥756.2B | ¥53.8B | ¥48.0B | ¥1.2T | +17.1% |
| 2021FY | ¥645.9B | ¥51.5B | ¥41.9B | ¥1.1T | — |
Sources: annual securities reports, earnings releases and other public disclosures (Jan 2026)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
